Stockscreener 앱 받기
35.95
0.53%
-0.185
전일 마감가:
$36.14
열려 있는:
$36.39
하루 거래량:
1.07M
Relative Volume:
0.49
시가총액:
$3.26B
수익:
$170.10M
순이익/손실:
$-239.59M
주가수익비율:
-12.84
EPS:
-2.8
순현금흐름:
$-191.20M
1주 성능:
-6.01%
1개월 성능:
+3.04%
6개월 성능:
-30.36%
1년 성능:
-32.87%
1일 변동 폭
$35.55
$37.34
1주일 범위
$33.03
$38.49
52주 변동 폭
$30.04
$67.88
크리스퍼 테라퓨틱스 Stock (CRSP) Company Profile
명칭
Crispr Therapeutics Ag
전화
(617) 315-4600
주소
BAARERSTRASSE 14, ZUG
CRSP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
35.95 | 3.26B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
431.25 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
537.59 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
554.43 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.88 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.26 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
크리스퍼 테라퓨틱스 Stock (CRSP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-14 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-02-12 | 업그레이드 | TD Cowen | Sell → Hold |
| 2025-02-03 | 개시 | H.C. Wainwright | Buy |
| 2024-08-06 | 재확인 | Needham | Buy |
| 2024-08-02 | 개시 | Rodman & Renshaw | Buy |
| 2024-06-28 | 재개 | Guggenheim | Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-11 | 다운그레이드 | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | 개시 | Mizuho | Buy |
| 2023-08-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-04-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-03-17 | 개시 | Bryan Garnier | Buy |
| 2023-03-07 | 개시 | Robert W. Baird | Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Underweight |
| 2022-08-09 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-04-21 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-03-04 | 개시 | JMP Securities | Mkt Outperform |
| 2020-12-10 | 재확인 | Chardan Capital Markets | Buy |
| 2020-12-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-10 | 재확인 | Needham | Buy |
| 2020-12-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | 개시 | BofA Securities | Buy |
| 2020-07-28 | 재확인 | Needham | Buy |
| 2020-07-14 | 개시 | SunTrust | Buy |
| 2020-06-15 | 재확인 | Canaccord Genuity | Buy |
| 2020-03-05 | 개시 | Stifel | Hold |
| 2020-02-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-11-19 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-08-01 | 개시 | Jefferies | Buy |
| 2019-07-26 | 개시 | Canaccord Genuity | Buy |
| 2019-06-10 | 개시 | ROTH Capital | Buy |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-14 | 개시 | William Blair | Mkt Perform |
| 2019-01-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-01-22 | 다운그레이드 | Citigroup | Neutral → Sell |
모두보기
크리스퍼 테라퓨틱스 주식(CRSP)의 최신 뉴스
Crispr Therapeutics: Complex Casgevy Launch, But Broader Gene-Editing Potential Still Shines - Seeking Alpha
Crispr Therapeutics (CRSP) Price Target Reduced by Barclays to $42 | CRSP Stock News - GuruFocus
Needham & Company LLC Lowers CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $81.00 - MarketBeat
Chardan Capital Cuts CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $82.00 - MarketBeat
CRISPR Therapeutics (NasdaqGM:CRSP) Q1 2025 Revenue Increases 71% to US$1 Million - Yahoo Finance
CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results - insights.citeline.com
CRISPR Therapeutics (CRSP): Goldman Sachs Lowers Price Target to $47 | CRSP Stock News - GuruFocus
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - The Motley Fool
June 27th Options Now Available For CRISPR Therapeutics - Nasdaq
Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet - Yahoo
CRISPR Therapeutics Struggles Under Slow Adoption And Regulatory Uncertainty (Downgrade) - Seeking Alpha
Bridgefront Capital LLC Makes New Investment in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Promising Developments and Pipeline Expansion at Crispr Therapeutics AG Support Buy Rating - TipRanks
Chardan Capital Remains a Buy on Crispr Therapeutics AG (CRSP) - The Globe and Mail
CRSP: Needham Maintains Buy Rating Despite Target Price Reductio - GuruFocus
Crispr Therapeutics Q1 Earnings Analysis: Ignore The Gloom, Stay The Course (NASDAQ:CRSP) - Seeking Alpha
CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst - Benzinga
CRSP Sees Price Target Adjustment by BofA Amid Key Updates | CRS - GuruFocus
CRISPR Therapeutics Q1 Earnings and Sales Miss Estimates, Stock Tanks - MSN
Crispr Therapeutics price target lowered to $79 from $80 at BofA - TipRanks
CRSP Sees Price Target Adjustment by BofA Amid Key Updates | CRSP Stock News - GuruFocus
CRSP: Needham Maintains Buy Rating Despite Target Price Reduction | CRSP Stock News - GuruFocus
These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results - Benzinga
CRSP Stock: Analyst Maintains Buy Rating, Lowers Price Target | CRSP Stock News - GuruFocus
Crispr Therapeutics AG: Promising Trial Results and Strong Financial Position Support Buy Rating - TipRanks
Crispr Therapeutics AG: Strong Buy Rating Backed by Promising Clinical Data and Strategic Collaborations - TipRanks
VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations - Yahoo Finance
Crispr Therapeutics (CRSP) Upgraded to Buy by Clear Street Analyst | CRSP Stock News - GuruFocus
Crispr Therapeutics upgraded to Buy from Hold at Clear Street - TipRanks
Crispr Therapeutics AG: Balancing Growth Potential with Profitability Challenges – Hold Rating - TipRanks
NKureCRISPR Therapeutics partner to develop off-the-shelf CAR-T therapy - BusinessLine
NkureCrispr Therapeutics partner to co-develop off-the-shelf CAR-T therapy - BusinessLine
NKure Therapeutics and CRISPR Therapeutics Partner to Advance CTX112 for Cancer Treatment in India - APN News
Dimensional Fund Advisors LP Has $37.28 Million Stake in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Nkure Therapeutics And CRISPR Therapeutics Partner To Advance CTX112™ For Cancer Treatment In India - Passionate In Marketing
Decoding CRISPR Therapeutics AG (CRSP): A Strategic SWOT Insight - GuruFocus
CRISPR (CRSP) Reports Wider Losses Amid Revenue Growth - GuruFocus
Crispr Therapeutics earnings missed by $0.37, revenue fell short of estimates - Investing.com
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
CRISPR Therapeutics AG reports results for the quarter ended March 31Earnings Summary - TradingView
CRISPR Therapeutics AG Reports Q1 2025 EPS of -$1.58 and Revenue of $865K, Missing Estimates - GuruFocus
Biotechnology: Crispr Therapeutics starts the year with higher loss | blue News - bluewin E-Mail
Crispr Therapeutics reports Q1 EPS ($1.58), consensus ($1.28) - TipRanks
CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3 - The Manila Times
VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View Tightened - Yahoo Finance
Baker BROS. Advisors LP Buys 464,936 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts - Seeking Alpha
Genome Engineering Market Generated Opportunities, Future - openPR.com
Susquehanna Fundamental Investments LLC Makes New Investment in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - MSN
크리스퍼 테라퓨틱스 (CRSP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.11%
0.83%
자본화:
|
볼륨(24시간):